BlossomHill doses first patient in SOLARA study’s expansion cohorts
BlossomHill Therapeutics has dosed the first subject in the expansion cohorts of the SOLARA Phase I/II trial to evaluate BH-30643…
All articles by RanjithKumar Dharma
RanjithKumar Dharma
-
-
Lighthouse secures $49.2m NIA grant for Alzheimer’s therapy trial
Lighthouse Pharmaceuticals has secured a grant of $49.2m from the National Institute on Aging (NIA), a division of the National…
-
Amylyx’s AMX0035 shows promise in Phase II Wolfram syndrome trial
Amylyx Pharmaceuticals has announced positive topline results from the Phase II HELIOS clinical trial, indicating sustained improvements with AMX0035 in…
-
Response begins enrolment for trial of RDX-002 for weight management
Response Pharmaceuticals has initiated subject enrolment for a Phase II trial of its drug candidate RDX-002, designed to manage weight…
-
Innovent’s trial of picankibart for ulcerative colitis meets primary endpoint
Innovent Biologics has reported that its Phase II clinical trial of picankibart (IBI112) in Chinese patients with moderately to severely…
-
Eximia Research acquires Integrated Clinical Trial Services
Integrated clinical trial network Eximia Research has expanded into Iowa, US, with the acquisition of Integrated Clinical Trial Services (ICTS).…
-
Piramal Pharma to expand Lexington sterile injectables facility in US
Piramal Pharma Solutions, a contract development and manufacturing organisation, has announced an $80m investment to expand its sterile injectables facility…
-
Aulos to begin Phase II portion of solid tumour therapy trial
Aulos Bioscience has unveiled plans to begin the Phase II portion of its Phase I/II clinical study of human IgG1…
-
MyMD to begin Phase II trial of rheumatoid arthritis therapy
MyMD Pharmaceuticals has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application…
-
Alentis doses first subject in organ fibrosis therapy trial
Alentis Therapeutics has dosed the first subject in a Phase II clinical study of its investigational monoclonal antibody, lixudebart, to…